KYMRKymera Therapeutics Inc
KYMR
Kymera Therapeutics Inc842
Mkt Cap
$6.94BVolume
399,731.0052W High
$103.0052W Low
$24.23PE Ratio
-23.12KYMR Fundamentals
Price
$85.05Prev Close
$87.35Open
$86.8650D MA
$82.53Beta
1.60Avg. Volume
728,278.34EPS (Annual)
-$3.69P/B
4.38Rev/Employee
$164,752.10$5,808.19
Kymera Therapeutics (NASDAQ:KYMR) Insider Noah Goodman Sells 2,000 Shares
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) insider Noah Goodman sold 2,000 shares of the stock in a transaction on Friday, April 10th. The shares were sold at an average price of $87.35, for a total value of $174,700.00. Following the sale, the insider owned 51,542 shares in the...
MarketBeat·2d ago
Kymera Therapeutics (NASDAQ:KYMR) Insider Noah Goodman Sells 8,264 Shares
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) insider Noah Goodman sold 8,264 shares of the stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of...
MarketBeat·2d ago
Noah Goodman Sells 2,000 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) insider Noah Goodman sold 2,000 shares of the stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average...
MarketBeat·2d ago
KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200
Kymera Therapeutics secures $45M as Gilead licenses KT-200, advancing a novel CDK2 degrader with potential in breast cancer and solid tumors.
Zacks·2d ago
SG Americas Securities LLC Grows Position in Kymera Therapeutics, Inc. $KYMR
SG Americas Securities LLC boosted its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 169.1% during the 4th quarter, according to the company in its most recent...
MarketBeat·7d ago
Elena Ridloff Sells 7,400 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Elena Ridloff sold 7,400 shares of Kymera Therapeutics stock in a transaction that occurred on Tuesday, March 31st. The stock was...
MarketBeat·10d ago
Kymera Therapeutics (NASDAQ:KYMR) Director Sells $631,738.00 in Stock
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Elena Ridloff sold 7,400 shares of Kymera Therapeutics stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $85.37, for a total value of $631,738.00. The transaction was disclosed in a document...
MarketBeat·10d ago
Jeremy Chadwick Sells 7,600 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) COO Jeremy Chadwick sold 7,600 shares of Kymera Therapeutics stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $85.38, for a total transaction of $648,888.00. Following the sale, the chief...
MarketBeat·10d ago
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) COO Sells $1,251,134.40 in Stock
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) COO Jeremy Chadwick sold 14,640 shares of the company's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $85.46, for a total value of $1,251,134.40. Following the completion of the transaction, the...
MarketBeat·10d ago
Kymera Therapeutics (NASDAQ:KYMR) Director Elena Ridloff Sells 4,600 Shares
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Elena Ridloff sold 4,600 shares of the firm's stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $85.42, for a total transaction of $392,932.00. The transaction was disclosed in a...
MarketBeat·10d ago
<
1
2
...
>